|Mr. Michael G. Raab||Pres, CEO & Director||780.56k||N/A||1965|
|Ms. Elizabeth A. Grammer||Exec. VP, Gen. Counsel, Sec. & Head of HR||504k||N/A||1964|
|Mr. David Rosenbaum||Chief Devel. Officer||521.64k||N/A||1961|
|Mr. Mark E. Kaufmann||CFO & Treasurer||N/A||N/A||1968|
|Mr. Jeffrey W. Jacobs||Sr. VP of Technical Operations||N/A||N/A||1963|
Ardelyx, Inc., a specialized biopharmaceutical company, develops and sells medicines for the treatment of cardio renal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.
Ardelyx, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 9.